Filing Flows › Comparisons › MIRM vs RARE
Mirum Pharmaceuticals vs Ultragenyx Pharmaceutical: MIRM and RARE compared
Mirum Pharmaceuticals is the larger company: $186M of revenue in its latest quarter (Q3 2026) against $173M for Ultragenyx Pharmaceutical (Q3 2026). Mirum Pharmaceuticals is growing faster (+40% against +8% a year earlier). Mirum Pharmaceuticals is more profitable, with an operating margin of -32.2% against -63.6%.
Where the money goes: MIRM and RARE
Mirum Pharmaceuticals (MIRM) · Q3 2026
Mirum Pharmaceuticals, Q3 2026: revenue $186M (+40% year over year), operating margin -32.2%, net loss $40.8M, operating cash flow −$4.3M. The chart follows the revenue to costs, profit and cash.
Ultragenyx Pharmaceutical (RARE) · Q3 2026
Ultragenyx Pharmaceutical, Q3 2026: revenue $173M (+8% year over year), operating margin -63.6%, net loss $118M, operating cash flow −$43.0M. The chart follows the revenue to costs, profit and cash.
| Mirum Pharmaceuticals (MIRM) | Ultragenyx Pharmaceutical (RARE) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q3 2026 |
| Revenue | $186M | $173M |
| Revenue growth, Y/Y | +40% | +8% |
| Operating margin | -32.2% | -63.6% |
| Net earnings | −$40.8M | −$118M |
| Net margin | -22.0% | -68.2% |
| Operating cash flow | −$4.3M | −$43.0M |
| Market value | — | $1.6B |
| Analysts’ mean target | — | $25.40 |
Where the revenue comes from
Mirum Pharmaceuticals
- Livmarli: $133M (72%)
- Bile Acid Medicines: $52.3M (28%)
Ultragenyx Pharmaceutical
- Product: $105M (61%)
- Royalty: $68.0M (39%)
Questions
Which is bigger, Mirum Pharmaceuticals or Ultragenyx Pharmaceutical?
Mirum Pharmaceuticals is the larger company: $186M of revenue in its latest quarter (Q3 2026) against $173M for Ultragenyx Pharmaceutical (Q3 2026).
Is Mirum Pharmaceuticals or Ultragenyx Pharmaceutical growing faster?
Mirum Pharmaceuticals is growing faster (+40% against +8% a year earlier).
Which is more profitable, Mirum Pharmaceuticals or Ultragenyx Pharmaceutical?
Mirum Pharmaceuticals is more profitable, with an operating margin of -32.2% against -63.6%.
More: Mirum Pharmaceuticals earnings · how Mirum Pharmaceuticals makes money · Ultragenyx Pharmaceutical earnings · how Ultragenyx Pharmaceutical makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Nov 3, 2026; 10-Q filed Nov 4, 2026). Fiscal quarters can end on different dates. Not investment advice.